Home DKmedtech Honored as National-Level "Key Little Giant" Enterprise, Advances Global Expansion with Innovative Vascular Intervention Solutions

DKmedtech Honored as National-Level "Key Little Giant" Enterprise, Advances Global Expansion with Innovative Vascular Intervention Solutions

Jun 09, 2025 09:00 CST Updated 09:00
DK Medtech

Vascular Interventional Balloon Product Developer



Recently, the Ministry of Industry and Information Technology of China authoritatively releasedCountryNational "Specialized, Precise, Unique, and Innovative" Key Little Giant EnterprisesList,DK Medical Technology (Suzhou) Co., Ltd.(DK Medtech) has been successfully selected due to its core technology breakthroughs in the vascular intervention field and outstanding market performance.

Image


About National-Level Specialized, Precise, Unique, and Innovative""Key Little Giant" Enterprises




National-level specialized and new "little giant" enterprises are already among the best of high-quality small and medium-sized enterprises in China, andNational Specialized and Innovative"Key Little Giant" enterprises are the "elite troops" further selected on this basis.With the core standard of "Three New and One Strong" (new momentum, new technology, new products, strengthening and supplementing the industrial chain), they focus on strategic emerging industries and future industries. They excel in "specialization, refinement, uniqueness, and innovation," possess key core technologies, have high market share, superior quality, and good benefits, making them an important force in driving industrial transformation, upgrading, and high-quality economic development.

This time, it was honored with the national-level specialized and new "Key Little GiantCorporate Title: An Important Milestone in DK Medtech's Development History. DK Medtech has been deeply engaged in the high-end vascular implant and interventional medical device field, particularly excelling in the balloon dilatation catheter sector. With its technical expertise and innovative spirit, DK Medtech has become a leading enterprise in treating vascular stenosis in the hemodialysis field in China. In terms of overseas market expansion, DK Medtech has recently achieved significant successes; its core scored products have officially entered the EU market, gaining high recognition from local authorities due to their outstanding performance and quality. Additionally, the company has established close cooperative relationships in multiple countries across Europe, the Middle East, and the Asia-Pacific region. It is also in deep negotiations with well-known U.S. companies, indicating DK Medtech’s promising growth potential and demonstrating its determination to further expand its presence in the global medical device market.

In the future, DK Medtech will continue to adhere to independent innovation, focus on cutting-edge technologies, increase R&D investment, deepen industry-university-research collaboration, and further promote technological breakthroughs, industrial upgrading, and international development of high-end medical devices produced in China, providing higher-quality medical solutions for patients worldwide.


Image
Scan the code to view: Announcement on the number of enterprises proposed to be supported in 2025 under the second batch of the new round and the third batch of the previous round for promoting high-quality development of specialized, refined, unique, and innovative small and medium-sized enterprises


Image

DK Medtech

DKmedtech

Since its establishment in 2015, DK Medtech has consistently adhered to innovation as its driving force and has become a leading Chinese enterprise in the full range of interventional balloon innovations. It has developed more than ten types of balloons, including standard balloons, high-pressure balloons, scoring balloons, and drug-coated scoring balloons. Its product line covers almost all vascular intervention fields, including cardiovascular, peripheral, and neurovascular interventions. Multiple products have received international certifications such as EU CE MDR and U.S. FDA. The company’s self-developed directional scoring technology is utilized in coronary scoring balloons, peripheral scoring balloons, and drug-coated scoring balloons. According to published pre-market RCT studies, its clinical performance demonstrates significantly better clinical benefits compared to imported control groups, achieving outstanding results and market position in niche markets.

Image